REVIEW

Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity

[version 1; peer review: 2 approved]

Sofie Bliddal ¹, Claus Henrik Nielsen², Ulla Feldt-Rasmussen¹

¹Department of Medical Endocrinology, Section 2132, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, 2100 Copenhagen, Denmark

²Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, section 7521, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, 2100 Copenhagen, Denmark

V1 First published: 28 Sep 2017, 6(F1000 Faculty Rev):1776
<https://doi.org/10.12688/f1000research.11535.1>

Latest published: 28 Sep 2017, 6(F1000 Faculty Rev):1776
<https://doi.org/10.12688/f1000research.11535.1>

Abstract

Autoimmune thyroid disease (AITD) is often observed together with other autoimmune diseases. The coexistence of two or more autoimmune diseases in the same patient is referred to as polyautoimmunity, and AITD is the autoimmune disease most frequently involved. The occurrence of polyautoimmunity has led to the hypothesis that the affected patients suffer from a generalized dysregulation of their immune system. The present review summarizes recent discoveries unravelling the immunological mechanisms involved in autoimmunity, ranging from natural autoimmunity to disease-specific autoimmunity. Furthermore, the clinical grounds for considering AITD in a setting of polyautoimmunity are explored. A better understanding of these may pave the way for designing new treatment modalities targeting the underlying immune dysregulation when AITD appears in the context of polyautoimmunity.

Keywords

Thyroid autoimmunity, polyautoimmunity, immunology, autoimmune disease, Graves' disease, Hashimoto's thyroiditis, AITD, antibodies

Open Peer Review

Approval Status

	1	2
version 1
28 Sep 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Maria Marazuela**, Universidad Autónoma de Madrid, Madrid, Spain
2. **Alessandro Antonelli**, University of Pisa, Via Savi 10, Italy

Any comments on the article can be found at the end of the article.

Corresponding author: Sofie Bliddal (sofiebliddal@gmail.com)

Competing interests: The authors declare that they have no competing interests.

Grant information: S. Bliddal is kindly supported by grants from the Copenhagen University Hospital (Rigshospitalet) and Musikforlæggerne Agnes and Knut Mørk's Foundation. U. Feldt-Rasmussen is supported by a grant from the Novo Nordisk Foundation. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2017 Bliddal S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Bliddal S, Nielsen CH and Feldt-Rasmussen U. **Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity [version 1; peer review: 2 approved]** F1000Research 2017, 6(F1000 Faculty Rev):1776 <https://doi.org/10.12688/f1000research.11535.1>

First published: 28 Sep 2017, 6(F1000 Faculty Rev):1776 <https://doi.org/10.12688/f1000research.11535.1>

Introduction

Autoimmune thyroid diseases (AITDs), comprising the two main entities Hashimoto's thyroiditis (HT) and Graves' disease (GD), are the most common autoimmune diseases¹ and are often observed together with other autoimmune diseases. The occurrence of two or more diseases in the same patient is often referred to as polyautoimmunity². This has led to the hypothesis that many patients with autoimmune disease, in general, suffer from an underlying dysfunction of critical mechanisms ensuring self-tolerance. The present review examines recent advances in the understanding of immunological aspects involved in autoimmunity, ranging from physiological to disease-specific autoimmunity, and explores the clinical grounds for considering thyroid autoimmunity in a setting of polyautoimmunity.

Immunological aspects of polyautoimmunity

Natural polyautoimmunity

At the beginning of the 20th century, Paul Ehrlich demonstrated that animals do not produce antibodies against their own red blood cells and coined the term "horror autotoxicus" for the immune system's reaction with the body's own constituents^{3,4}. At the same time, the normal occurrence of autoantibodies against spermatozoa was demonstrated⁵. Since then, many studies have shown the existence of autoantibodies in healthy animals and humans, referred to as natural autoantibodies^{6,7}. In general, natural autoantibodies show broad reactivity against more self- and non-self-antigens and are of the IgM isotype^{6,8}, whereas disease-associated autoantibodies are of the IgG isotype and bind specific self-antigens with high affinity^{9,10}. At least in mice, the subset of B cells producing natural

autoantibodies appears to be positively selected for self-reactivity in the bone marrow¹¹. Although B cells and T cells binding to "self" with high affinity are negatively selected, self-reactive lymphocytes with low-affinity receptors are allowed to escape and enter the circulation but often without harmful consequences^{12,13}. Thus, natural autoantibodies may serve a role in the clearance of aging cells and cells with tumor potential and may also exert anti-inflammatory control over B cells and T cells^{14,15}. Natural autoimmunity should therefore be distinguished from disease-associated autoimmunity.

Loss of self-tolerance

Autoimmune disease is preceded by loss of immunological self-tolerance, which may occur at the central level (during the selection processes described above) or in the periphery. The adaptive immune system's T cells and B cells usually keep the balance between reacting aptly toward foreign antigens and avoiding attack on "self". Both T cells and B cells contain subsets of regulatory cells with an immunoregulatory cytokine profile on the one hand and effector cells that produce antibodies or secrete pro-inflammatory cytokines on the other (Figure 1). Thus, the traditional view of a T helper type 1 (Th1)/Th2 dichotomy has been abandoned since it became clear that CD4⁺ effector T cells can differentiate into several subsets of Th cells which stimulate different parts of the immune system: for example, Th1 cells stimulate cellular immunity and the production of opsonizing antibodies, Th2 cells stimulate IgE production, and Th17 cells stimulate neutrophils. Th1 cells and Th17 cells have been shown to play detrimental roles in many autoimmune diseases, including HT and GD^{16,17}. Furthermore, Th17 cells have been associated with chronic

Figure 1. B-cell and T-cell subsets controlling autoimmunity. Peripheral self-tolerance is ensured by regulatory B cells and T cells. Autoimmunity (loss of self-tolerance) is considered to be due to a shift in favor of pro-inflammatory effector cells. B_{eff}, effector B cells; B_{reg}, regulatory B cells; DC, dendritic cell; IL, interleukin; iT_{reg}, induced regulatory T cells; TGF-β, transforming growth factor beta; Th_{1,2,17}, effector CD4⁺ T-cell subsets with different cytokine profiles.

inflammation and autoimmune diseases such as systemic lupus erythematosus, Sjögren's syndrome, and systemic sclerosis¹⁸.

Regulatory T cells (Tregs) are primarily responsible for maintaining self-tolerance, and a protective role of Tregs has been demonstrated in several animal models of autoimmune diseases^{19,20}. A subset of Tregs known as natural Tregs (nTregs) leave the thymus as fully differentiated cells, whereas another subset, inducible Tregs (iTregs), can be induced from naïve Th0 cells²¹. Both subsets are characterized by the expression of the transcription factor forkhead box protein 3 (FOXP3) and mediate their action in part via the secretion of interleukin-10 (IL-10) and transforming growth factor beta (TGF- β)²² and in part by mechanisms involving cell-to-cell contact²³. Loss of peripheral self-tolerance is considered to be the result of an overweight of Th17 cell response as compared with induced regulatory Th10 cell response¹⁸. FOXP3 is involved in the peripheral self-tolerance processes by promoting the development of Tregs while inhibiting the differentiation of Th17 cells²¹. Mutations of the *Foxp3* gene can cause the immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, an early-onset, life-threatening autoimmunity characterized by substantial polyautoimmunity and often death within two years of birth²⁴. Under less severe circumstances, overexpression of FOXP3 Δ 2, a splice variant of FOXP3 lacking exon 2²⁵, may be associated with a shift toward a Th17 response, thereby increasing autoantibody production, as shown in a recent study of patients with HT²⁶. Accordingly, a skewed balance between Th17 cells and Tregs^{18,21,26} as well as dysfunctional Tregs¹⁹ have been demonstrated in autoimmune disease in humans. A shift between Th10 and Th17 cells may occur according to the cytokine milieu in the microenvironment^{18,27}. Recently, regulatory B cells (Bregs) have received much attention as inhibitors of inflammatory and autoimmune responses by the production of

regulatory cytokines (primarily IL-10)¹⁸. Another factor that may contribute to the development of autoimmune disease is therefore a cytokine expression dominated by effector B cells rather than by Bregs. Thus, both Tregs and Bregs contribute to the maintenance of peripheral tolerance (Figure 1).

Development of autoimmune disease

The transition from natural to clinically manifesting autoimmunity relies on an interplay between genetic predispositions and environmental events, as depicted in Weetman's "Swiss cheese model" on AITD (Figure 2)²⁸. Most autoimmune diseases are associated with specific variants of the human leukocyte antigen (*HLA*) genes. Several other genetic polymorphisms have been associated with autoimmune diseases, particularly some located at the genes encoding cytotoxic T lymphocyte-associated 4 (CTLA-4) and the protein tyrosine phosphatase, non-receptor type 22 (PTPN22)²⁹. Each of these loci encodes molecules involved in the regulation of T cells. In particular, two rare syndromes illustrate the importance of T cells in maintaining self-tolerance: the first, autoimmune polyglandular syndrome type I (APS 1, also called APECED), is caused by defects in the autoimmune regulator (*AIRE*) gene that mediates the induction of T-cell self-tolerance in the thymus³⁰. In patients with APS 1, multiple endocrine glands are dysfunctional. The second, FOXP3 deficiency, is associated with the IPEX syndrome, as mentioned above. Whereas APS 1 and IPEX syndrome are caused by mutation of a single gene, most cases of autoimmunity are likely the result of a broad range of genetic predispositions and environmental factors resulting in an imbalance of the peripheral self-tolerance mechanisms sustained by Tregs and Bregs (Figure 1)¹⁸. Thus, genetic polymorphisms in self-antigens, cytokines, estrogen receptors, and adhesion molecules have also been linked to the development of autoimmune disease^{28,31–36}, as have genes coding for apoptotic processes³⁷.

Figure 2. Etiology of thyroid autoimmunity. The development of autoimmune thyroid disease is a result of multiple events—a "Swiss cheese model". Figure reproduced with kind permission from Weetman²⁸. HLA, human leukocyte antigen.

In addition to genetic variation, both post-transcriptional and post-translational events may contribute to the development of autoimmunity. Thus, translation of mRNA into protein may be regulated by binding of RNA-binding protein and microRNAs, and alternative splicing of mRNA may influence the functionality of encoded proteins³⁸. As mentioned above, certain splice variants of FOXP3 mRNA have been associated with autoimmune disease, including HT^{26,39,40}. An example of post-translational modification that enhances the immunogenicity of self-proteins is the conversion of arginine residues into citrulline residues, which has a major impact on autoantibody formation in rheumatoid arthritis⁴¹.

Several environmental factors may trigger autoimmune disease in genetically predisposed individuals, including bacterial and viral infections, cigarette smoking, maternal-fetal microchimerism^{42,43}, and exposure to chemical compounds (flame retardants and phthalates)⁴⁴, to mention but a few. Finally, being female predisposes to many autoimmune diseases, which may relate to hormonal factors and to X-chromosome inactivation patterns^{45,46}.

Autoimmune thyroid disease

AITD is increasingly viewed as a continuum not only including distinct disease entities—that is, HT, GD, subacute thyroiditis, primary myxedema, and Graves' orbitopathy (GO)—but covering a spectrum of diseases affecting the thyroid gland. However, in most thyroid research and in clinical practice, the two main entities of AITD remain as GD and HT with typically opposing main clinical manifestations: hyperthyroidism and hypothyroidism, respectively. In line with a more flexible view of AITD, both HT and GD are heterogeneous and can cause both hyperthyroidism and hypothyroidism⁴⁷, even alternating between one form and the other⁴⁸. GD and HT are among the most common autoimmune diseases in Western countries⁴⁹. The pathogenesis is complex with a wide range of predisposing environmental, endogenous, and genetic factors, as described above and specified in relation to AITD in [Box 1](#)^{45,46,50–52}.

HT is characterized by a direct T-cell attack on the thyroid gland, leading to thyroiditis and subsequent exposure of thyroid antigens (thyroid peroxidase and thyroglobulin) against which antibodies are then produced. Thyroglobulin antibodies (TgAbs) and thyroid peroxidase antibodies (TPOAbs) are commonly associated with HT with a destructive pattern and are considered diagnostic for this disease. In any iodine-sufficient population, however, the prevalence of TPOAbs and TgAbs is much higher than that of clinical disease, amounting to approximately 15–25%, with the highest prevalence in females and increasing with age⁵³. GD is also primarily caused by a T-cell abnormality, but the hyperthyroidism associated with the disease is caused by the production of the pathognomonic thyrotropin receptor autoantibodies (TRAbs). The stimulating effect of TRAbs on thyrocytes probably has an influence on the formation of TgAbs and TPOAbs as well⁵⁴. GD (and less commonly HT) can be complicated by GO, an autoimmune reaction in the orbita causing fibroadipose tissue and extraocular muscles to increase in size with a risk of permanent damage to the optic nerve. Shared antigens between the thyroid and orbita have been suspected to be the target of the autoimmune response, and TRAbs are likely to play a part in the pathogenesis. A general inflammatory cytokine profile

Box 1. Risk factors for autoimmune thyroid disease

Environmental

- Iodine consumption
- Smoking (possibly protective)
- Radiation
- Drugs (including biologic agents)
- Alcohol consumption (protective)
- Pollutants
- Selenium? Vitamin D?
- Infections (*Yersinia enterocolitica*)?
- Improved hygiene?

Endogenous

- Female sex
- Parity
- Aging
- Stress hormones
- Fetal microchimerism

Genetic

- Chromosome abnormalities
- Human leukocyte antigen types?
- Single-nucleotide polymorphisms?

(mainly Th1-driven) and autoimmune reactions toward the insulin-like growth factor 1 receptor (IGF-1R) have been demonstrated as well⁵⁵.

Polyautoimmune disease

Occasionally, patients suffer from more than one well-defined autoimmune disease. In the 1950s, it was recognized that certain “shared threads” characterized autoimmune diseases^{56,57}, a notion which has since been the subject of much debate and research. Many terms have been suggested for such conditions: polyautoimmunity^{2,58}, autoimmune diathesis⁵⁷, autoimmune tautology⁵⁹, or, in the case of three or more coexisting autoimmune diseases, multiple autoimmune syndromes⁶⁰. Lack of a common terminology challenges any comprehensive literature search and review. In the following, the term “polyautoimmunity” is used to describe the coexistence of two or more autoimmune diseases in the same patient.

Several endocrine syndromes including more than one autoimmune disease have been described (a sample of them is illustrated in [Table 1](#)^{61–64}). In polyglandular autoimmune syndrome type 2, Addison's disease occurs with AITD or type 1 diabetes (as well as with other autoimmune presentations)⁶¹. Such syndromes or classified clusters are rare in contrast to the presence of multiple autoantibodies (independent of clinical diagnoses) in patients with autoimmune disease. AITD, being the most common, is prevalent in most polyautoimmune syndromes and cases. The following sections describe the clinical findings related to thyroid autoimmunity in association with other autoimmunity.

Table 1. Polyautoimmune endocrine syndromes including thyroid disease.

Clusters	Proposed pathogenic mechanism
Autoimmune polyglandular syndromes ⁶¹	
Type I (autoimmune polyglandular syndrome type I or Whitaker syndrome): mucosal and cutaneous <i>Candida</i> infections, Addison's disease, hyposplenism, hypoparathyroidism, and multiple autoimmune presentations (that is, hypothyroidism, hypogonadism, vitiligo, alopecia, pernicious anemia, and chronic autoimmune hepatitis)	Mutation of autoimmune regulator (<i>AIRE</i>) gene involved in central tolerance development. Phenotype possibly affected by human leukocyte antigen (HLA) subtypes ⁶² .
Type II (Schmidt's syndrome): Addison's disease and hypothyroidism or type 1A diabetes as well as pernicious anemia, primary hypogonadism, vitiligo, celiac disease, and myasthenia gravis (by some further classified in types III and IV according to specific entities above)	Polygenetic with increased risk of disease linked to specific HLA-DR and HLA-DQ genotypes ⁶³
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome ²⁴ Immune dysfunction, enteropathy, dermatitis, autoimmune endocrinopathies (often type 1 diabetes and autoimmune thyroid disease), autoimmune skin diseases (that is, bullous pemphigoid), and multiple organ involvement	Mutation of <i>FOXP3</i> gene on the X chromosome
Multiple autoimmune syndromes ⁶⁰	
Type I: myasthenia gravis, thymoma, polymyositis, and giant cell myocarditis	
Type II: Sjögren's syndrome, rheumatoid arthritis, primary biliary cirrhosis, scleroderma, and autoimmune thyroid disorders	
Type III: autoimmune thyroid disease, myasthenia and/or thymoma, Sjögren's syndrome, pernicious anemia, idiopathic thrombocytopenic purpura, Addison's disease, insulin-dependent diabetes, vitiligo, autoimmune hemolytic anemia, and systemic lupus erythematosus	Genetic predisposition, with phenotype HLA B8 and/or DR3 or DR5 seeming to be an important factor
Thyrogastric cluster ⁶⁴ Autoimmune thyroiditis, chronic gastritis/pernicious anemia, and autoimmune adrenalitis (Addison's)	Polygenetic
Lupus-associated cluster ⁶⁴ Autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, and Sjögren's syndrome	Polygenetic
Trisomy 21 and Turner syndrome ⁶⁴ Chronic thyroiditis, type 1A diabetes, and others	Chromosomal abnormalities
Kearns-Sayre syndrome ⁶⁴ External ophthalmoplegia, retinal degeneration, diabetes, thyroiditis, and hypoparathyroidism	Mitochondrial myopathy

Thyroid autoimmunity in association with polyautoimmunity

Thyroid autoimmunity in other autoimmune disease

It is beyond the scope of this review to cover the numerous case reports describing polyautoimmunity. Instead, the present review will focus on clinical studies on polyautoimmunity involving AITD. In many studies, no distinction has been made between the various clinical phenotypes of AITD, and TgAbs, TPOAbs, and even TRAbs are often just referred to as "thyroid autoantibodies", making reported percentages indicative only.

In a Colombian study², patterns of clustering were investigated among 1,083 patients. The patients had systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, or multiple sclerosis. AITD was the most prevalent disease, coexisting with systemic sclerosis in 23% of cases, rheumatoid arthritis in 21% of cases, systemic lupus erythematosus in 18% of cases, and multiple sclerosis in 9%². No control group was provided to substantiate the findings. Among 479 patients with primary Sjögren's syndrome, Zeher *et al.* found 21% with AITD⁶⁵. Another study from the same group showed that HT was significantly more prevalent than GD

in patients with mixed connective tissue disease, rheumatoid arthritis, and Sjögren's syndrome and that both AITDs were much more prevalent in such patients than in the background population⁶⁶. A total of 8.2% of investigated patients with the investigated systemic autoimmune diseases had AITD based on clinical evaluation, imaging, and fine needle aspiration cytology⁶⁶.

A few studies of autoantibody prevalence have included healthy controls. Nakamura *et al.*⁶⁷ found significant increases in TgAb and TPOAb positivity in all investigated autoimmune diseases compared with healthy controls: up to 50% in type 1 diabetes, 55% in autoimmune liver disease, 26% in myasthenia gravis, and 34% in connective tissue diseases⁶⁷. Only patients with type 1 diabetes had TRAbs more often than healthy controls (20% versus 0%, $P < 0.01$). Interestingly, Liao *et al.*⁶⁸ found no significant difference in thyroid autoantibody positivity between 1,290 patients with rheumatoid arthritis and 1,236 controls without rheumatic disease (TPOAbs 15.6% versus 15.9%, TgAbs 1.1% versus 0.7%, $P > 0.05$)⁶⁸. We have previously found TPOAbs in 5% of patients with rheumatoid arthritis, 19% with type 1 diabetes mellitus, 11% with Sjögren's syndrome, 56% with pernicious anemia, and 22% with primary biliary cirrhosis compared with 98% with HT and 7% in healthy controls, which is in keeping with the above-mentioned increased risk of autoimmune disease and not only positivity for autoantibody⁶⁹.

Non-thyroid autoantibodies and other autoimmune disease in autoimmune thyroid disease

Few studies have investigated the prevalence of non-thyroid autoantibodies or other autoimmune diseases in patients with AITD. In a recently published prospective study, 3,069 patients with chronic AITD were compared with 1,023 patients with non-toxic nodular goiter and 1,023 healthy controls⁷⁰. Diagnosis of autoimmune disease was confirmed by a specialist according to scientific societies' criteria. Several of the concurrent autoimmune diseases were significantly more prevalent in patients with AITD than in the healthy controls. However, only three concurrent diseases had a prevalence of more than 2% in the AITD group: chronic autoimmune gastritis, vitiligo, and rheumatoid arthritis. Among observed clusters of disease, AITD together with chronic autoimmune gastritis and vitiligo formed a cluster with a significantly increased prevalence in the group of patients with AITD (12 patients versus 0 in other groups, $P = 0.02$)⁷⁰.

In a Japanese population of patients with AITD, anti-glutamic acid decarboxylase antibodies were the most prevalent non-thyroid autoantibodies, being present in 6.4% of GD and in 4.6% of patients with HT⁶⁷, thus confirming historical links between insulin antibodies and thyroid autoimmunity⁷¹. In a study of more than 3,000 UK patients with AITD, there was a significantly increased relative risk of any other autoimmune disease screened for compared with the background population⁷². Thus, 14.3% of the 495 patients with HT and 9.7% with GD had at least one other autoimmune disease, mainly type 1 diabetes, rheumatoid arthritis, and pernicious anemia. Wiebolt *et al.* investigated 359 patients with HT and 523 with GD and found differing patterns of autoantibody clustering in the two diseases⁷³. Thus, adrenal autoimmunity combined with beta-cell or gastric autoimmunity was more common in patients with HT compared with patients with GD⁷³.

Epidemiological studies

Lack of power in clinical studies is made up for in epidemiologic studies. Eaton *et al.* included data from more than 5 million Danes from hospital registries to investigate the prevalence of 31 specified autoimmune diseases (based on the International Classification of Diseases 10th Revision (ICD10) classification system)^{74,75}. Although data were limited to that of specialized care, the estimated lifetime prevalence of any autoimmune disease was 5.3%, and AITD most often coexisted with adrenal disease (odds ratio (OR) 12.9), alopecia areata (OR 11.4), vitiligo (OR 7.9), and pernicious anemia (OR 5.6)⁷⁵. However, compared with connective tissue diseases in particular, AITD showed limited overlap with other autoimmune diseases. As many patients with autoimmune disease are handled in general practice, a British study used the United Kingdom General Practice Research Database to study the intra-individual risk of polyautoimmunity⁷⁶. Along with large numbers of patients with insulin-dependent diabetes mellitus, rheumatoid arthritis, and multiple sclerosis, 26,198 patients with AITD were included. Patients with either AITD or rheumatoid arthritis were at risk of developing the other disease (sex-specific standardized incidence rate of 130.4–162.0)⁷⁶. The risk of patients with type 1 diabetes having AITD was increased significantly in comparison with the background population having AITD; with a prevalence six times higher in males and a prevalence four times higher in females. This is in keeping with at least one previous cohort study, where patients with two autoimmune diseases, and thus probably stronger influence of genetic than environmental or other inherent factors, seemed to show a diminished or even abolished female preponderance of autoimmune diseases that is otherwise observed in the general population⁷⁷. Thus, the *a priori* likelihood of contracting a second autoimmune disease is higher in males than in females with one autoimmune disease, which should be taken into account when managing male patients with AITD. Despite many inherent limitations, epidemiological studies provide further evidence of an increased risk of polyautoimmunity in patients with AITD. Without proving causality, the association between AITD and other autoimmune diseases seems well substantiated and with no strict distinction between organ-specific and non-organ-specific autoimmune disease.

Clinical consequences of polyautoimmunity in thyroid autoimmunity

Clinical impact of (poly)autoimmunity

The chronic nature of autoimmune disease implies high socioeconomic costs as well as a profound impact on the patient's health and well-being⁷⁸. The occurrence of polyautoimmunity rather than an isolated autoimmune disease may greatly affect prognosis. In a Dutch study, TPOAb positivity in patients with rheumatoid arthritis was predictive of disease activity—measured by the Disease Activity Score using 28 joint counts (DAS28)—and of increased carotid intima-media thickness at a 2-year follow-up⁷⁹. The latter finding may indicate an increased risk of cardiovascular disease in patients with polyautoimmunity in accordance with the well-established association between increased inflammation and risk of cardiovascular disease^{80,81}. In studies of reproductive failure, especially autoantibodies involved in the anti-phospholipid syndrome (that is, anti-cardiolipin antibodies)⁸² but also thyroid autoantibodies^{83,84} have been associated with worsened pregnancy

outcomes. In a study by Iijima *et al.*⁸⁵, several autoantibodies were analyzed, and women with autoantibodies against one or more self-antigens had a significantly increased risk of miscarriage. However, only 5% of all women (25.8% of autoantibody-positive women) had multiple autoantibodies⁸⁵. In women with recurrent pregnancy loss, a thorough examination of possible polyautoimmune etiology is therefore warranted, and immunotherapy appears to be beneficial⁸⁶.

Few studies indicate an impact of an underlying immunological tolerance breach rather than thyroid dysfunction on the symptomatology involved in AITD. Abnormal brain perfusion in patients with euthyroid HT compared with controls has led to a hypothesis of an autoimmune component in decreased vascularization, possibly causing psychiatric symptoms in patients with AITD^{87,88}. Also, a study of patient-reported outcomes (PROs) in Danish patients with AITD found a significant continuous reduction of outcomes, including physical functioning despite euthyroidism⁸⁹. A subsequent study found reduced PROs in patients with GD compared with patients with toxic nodular goiter but failed to show an association with thyroid antibody levels⁹⁰. Conversely, in studies of patients with systemic sclerosis and myasthenia gravis, those with coexistent AITD were less affected by their disease than patients without thyroid autoimmunity^{91,92}. Thus, quantitative increments of autoimmune diagnoses are not always associated with a worsened prognosis.

The possible negative attribution of underlying autoimmunity (for example, GD) rather than thyroid function impairment (for example, multinodular goiter) needs further investigation. The presence of a more general but undiagnosed polyautoimmunity could explain the poorer outcomes of treatment. This has in recent years been acknowledged by endocrinologists and is now introduced in clinical guidelines (for example, for the treatment of hypothyroidism)⁹³. Before combination therapy with thyroxine and triiodothyronine is considered, a search for other autoimmune diseases in a patient with AITD and poor PROs is now mandatory⁹³. Thus, it has become relevant to both the clinician and the patient with AITD to be aware of the possibility of polyautoimmunity, not only as an explanatory model of prolonged symptoms but also with respect to a possible altered prognosis of disease and treatment outcome.

The role of immunomodulatory biologic drugs

The prevalence of thyroid and other autoimmunity will likely be affected by the increasing administration of biologic agents in cancer treatment and internal medicine, developed to target specific parts of the immune system. In multiple sclerosis patients treated with the T cell-depleting anti-CD52 monoclonal antibody alemtuzumab, one third of patients developed GD between 6 and 31 weeks after treatment⁹⁴. This was likely due to loss of T cell-mediated immunoregulation. Also, in patients with chronic hepatitis treated with interferon-alpha, up to 40% developed thyroid autoantibodies and 15% developed clinical AITD^{95,96}. Stefan *et al.* found a direct impact of interferon-alpha on the activity of a thyroglobulin promoter region with a specific single-nucleotide polymorphism involved in AITD⁹⁷. Finally, biologic drugs stimulating the patient's own immune response against cancer cells have proven efficient in fighting cancers but may induce various autoimmune diseases. Among such drugs are the checkpoint inhibitors ipilimumab (a monoclonal antibody targeting the CTLA-4 receptor) and

nivolumab and pembrolizumab (blocking “programmed cell death 1” proteins on T cells, thus promoting anti-tumor activity). Autoimmune hypophysitis is seen in 4% of patients treated with ipilimumab and in 1% of patients treated with nivolumab or pembrolizumab. Combined treatment with ipilimumab and nivolumab increases the hypophysitis rate to 8%⁹⁸. In these patients with autoimmune hypophysitis, secondary adrenal insufficiency develops in up to 100%, hypogonadotropic hypogonadism in up to 85%, and central hypothyroidism in up to 100%⁹⁸. More rarely, autoimmune primary thyroid affection or adrenal insufficiency occurs⁹⁹. Thus, the use of such drugs should entail a standardized monitoring program to check for endocrinopathies (i.e. life-threatening adrenal insufficiency) and thorough patient information including which symptoms to react upon.

On the other hand, biologic agents may offer new options for treating (poly)autoimmune diseases, including otherwise treatment-resistant AITD. Treatment of rheumatic arthritis patients with biologic agents seems to be safe and to possibly have a positive effect on concurrent AITD¹⁰⁰. In a small study, the treatment of 138 patients with rheumatoid arthritis with the tumor necrosis factor-alpha inhibitor adalimumab led to concurrent improvement of hypothyroidism as well as a reduction in TPOAb levels¹⁰¹. Incorporation of rituximab, a B cell-depleting agent, has shown promising results in patients with GO^{102–104} in addition to ameliorating numerous other autoimmune diseases, such as rheumatoid arthritis^{103,105}, multiple sclerosis¹⁰⁶, and type 1 diabetes¹⁰⁷. In a recent study, inhibition of the IGF-1R by use of teprotumumab, an antibody targeting the IGF-1R, also significantly improved outcome in 88 patients with GO¹⁰⁸. The field of drugs targeting immune-mediated diseases is quickly evolving, and numerous drugs have been developed and are undergoing clinical trials¹⁰⁹. Although the mechanisms triggering loss of self-tolerance are still unclear, the increasing knowledge about B-cell and T-cell subsets and different cytokine milieus provides interesting perspectives for refined treatment options in (poly)autoimmune diseases including treatment-resistant AITD. For a summary of learning points, see [Box 2](#).

Conclusions

As illustrated above, AITD is often represented in patients with polyautoimmunity, and patients with AITD have an increased risk

Box 2. Learning points

- Polyautoimmunity in patients with autoimmune thyroid disease is common but not part of routine screening.
- Polyautoimmunity may increase morbidity due to inflammation.
- Patients with continuous complaints despite euthyroidism may benefit from wider immunological assessment.
- Interdisciplinary assessment is beneficial for polyautoimmune patients.
- Immunomodulatory biologic drugs may be a future treatment option in thyroid autoimmune patients with multiple associated autoantibodies.

of developing other autoimmune diseases. In AITD patients with remaining complaints despite euthyroidism or patients presenting with new symptoms, polyautoimmunity should come to mind. Furthermore, the concept of polyautoimmunity may call for a rethinking of treatment strategies in patients with AITD. Current treatment of AITD has focused on securing thyroid hormone homeostasis, but in cases with polyautoimmunity more attention should be drawn to the identification and treatment of the underlying immune dysregulation and inflammation. In years to come, immunomodulatory biologic drugs may serve this purpose.

Author contributions

SB was in charge of the manuscript preparation. All authors contributed to the conception, discussion, critical review, and approval

of the manuscript in accordance with the requirements of the International Committee of Medical Journal Editors. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

Competing interests

The authors declare that they have no competing interests.

Grant information

SB is kindly supported by grants from the Copenhagen University Hospital (Rigshospitalet) and the Musikforlæggerne Agnes and Knut Mørk Foundation. UF-R is supported by a grant from the Novo Nordisk Foundation.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Weetman A, DeGroot LJ: **Autoimmunity to the Thyroid Gland**. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, *et al.*, editors. *Endotext*. South Dartmouth (MA); 2000.
[PubMed Abstract](#)
- Rojas-Villarraga A, Amaya-Amaya J, Rodríguez-Rodríguez A, *et al.*: **Introducing polyautoimmunity: secondary autoimmune diseases no longer exist**. *Autoimmune Dis*. 2012; 2012: 254319.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ehrlich P: **Verh Ges Dtsch Naturforsch**. 1902; 1: 250–275.
- Welch WH: **The Huxley Lecture on Recent Studies of Immunity, with Special Reference to their Bearing on Pathology: Delivered at the Opening of the Winter Session of Charing Cross Hospital Medical School on October 1st, 1902**. *Br Med J*. 1902; 2(2180): 1105–14.
[PubMed Abstract](#) | [Free Full Text](#)
- Metchnikoff S: *Ann Inst Pasteur*. 1900; 14: 577–589.
- Avrameas S, Selmi C: **Natural autoantibodies in the physiology and pathophysiology of the immune system**. *J Autoimmun*. 2013; 41: 46–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nakamura M, Burastero SE, Ueki Y, *et al.*: **Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus**. *J Immunol*. 1988; 141(12): 4165–72.
[PubMed Abstract](#)
- Berneman A, Guilbert B, Eschrich S, *et al.*: **IgG auto- and polyreactivities of normal human sera**. *Mol Immunol*. 1993; 30(16): 1499–510.
[PubMed Abstract](#)
- Nielsen CH, Bendtzen K: **Immunoregulation by naturally occurring and disease-associated autoantibodies: binding to cytokines and their role in regulation of T-cell responses**. *Adv Exp Med Biol*. 2012; 750: 116–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nielsen CH, Brix TH, Gardas A, *et al.*: **Epitope recognition patterns of thyroid peroxidase autoantibodies in healthy individuals and patients with Hashimoto's thyroiditis***. *Clin Endocrinol (Oxf)*. 2008; 69(4): 664–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hayakawa K, Asano M, Shinton SA, *et al.*: **Positive selection of natural autoreactive B cells**. *Science*. 1999; 285(5424): 113–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nossal GJ: **Negative selection of lymphocytes**. *Cell*. 1994; 76(2): 229–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Webb S, Morris C, Sprent J: **Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity**. *Cell*. 1990; 63(6): 1249–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lutz HU, Binder CJ, Kaveri S: **Naturally occurring auto-antibodies in homeostasis and disease**. *Trends Immunol*. 2009; 30(1): 43–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hurez V, Dietrich G, Kaveri SV, *et al.*: **Polyreactivity is a property of natural and disease-associated human autoantibodies**. *Scand J Immunol*. 1993; 38(2): 190–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rapoport B, McLachlan SM: **Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease**. *J Clin Endocrinol Metab*. 2014; 99(11): 4060–1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Figuerola-Vega N, Alfonso-Pérez M, Benedicto I, *et al.*: **Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis**. *J Clin Endocrinol Metab*. 2010; 95(2): 953–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Papp G, Boros P, Nakken B, *et al.*: **Regulatory immune cells and functions in autoimmunity and transplantation immunology**. *Autoimmun Rev*. 2017; 16(5): 435–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Ramos-Leví AM, Marazuela M: **Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms**. *Endocrinol Nutr*. 2016; 63(8): 421–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Morris GP, Brown NK, Kong YM: **Naturally-existing CD4(+)CD25(+)Foxp3(+) regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen**. *J Autoimmun*. 2009; 33(1): 68–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- González-Amaro R, Marazuela M: **T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity**. *Endocrine*. 2016; 52(1): 30–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Roncarolo MG, Gregori S, Battaglia M, *et al.*: **Interleukin-10-secreting type 1 regulatory T cells in rodents and humans**. *Immunol Rev*. 2006; 212: 28–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
- von Boehmer H: **Mechanisms of suppression by suppressor T cells**. *Nat Immunol*. 2005; 6(4): 338–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bennett CL, Christie J, Ramsdell F, *et al.*: **The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3**. *Nat Genet*. 2001; 27(1): 20–1.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Allan SE, Passerini L, Bacchetta R, *et al.*: **The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs**. *J Clin Invest*. 2005; 115(11): 3276–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kristensen B, Hegedüs L, Madsen HO, *et al.*: **Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis**. *Clin Exp Immunol*. 2015; 180(1): 58–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yanaba K, Bouaziz J, Haas KM, *et al.*: **A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses**. *Immunity*. 2008; 28(5): 639–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Weetman AP: **The immunopathogenesis of chronic autoimmune thyroiditis one century after hashimoto**. *Eur Thyroid J*. 2013; 1(4): 243–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

29. Brand O, Gough S, Heward J: **HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity?** *Expert Rev Mol Med*. 2005; 7(23): 1–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Mathis D, Benoist C: **Aire. Annu Rev Immunol**. 2009; 27: 287–312.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Caputo M, Rivolta CM, Mories T, *et al.*: **Analysis of thyroglobulin gene polymorphisms in patients with autoimmune thyroiditis.** *Endocrine*. 2010; 37(3): 389–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. **F** Zenewicz LA, Abraham C, Flavell RA, *et al.*: **Unraveling the genetics of autoimmunity.** *Cell*. 2010; 140(6): 791–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
33. Johar AS, Mastronardi C, Rojas-Villarraga A, *et al.*: **Novel and rare functional genomic variants in multiple autoimmune syndrome and Sjögren's syndrome.** *J Transl Med*. 2015; 13: 173.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Johar AS, Anaya JM, Andrews D, *et al.*: **Candidate gene discovery in autoimmunity by using extreme phenotypes, next generation sequencing and whole exome capture.** *Autoimmun Rev*. 2015; 14(3): 204–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Chu X, Pan CM, Zhao SX, *et al.*: **A genome-wide association study identifies two new risk loci for Graves' disease.** *Nat Genet*. 2011; 43(9): 897–901.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Lee HS, Kang J, Yang S, *et al.*: **Susceptibility influence of a PTPN22 haplotype with thyroid autoimmunity in Koreans.** *Diabetes Metab Res Rev*. 2011; 27(8): 878–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. **F** Johar A, Sarmiento-Monroy JC, Rojas-Villarraga A, *et al.*: **Definition of mutations in polyautoimmunity.** *J Autoimmun*. 2016; 72: 65–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
38. **F** Chen JQ, Papp G, Szodoray P, *et al.*: **The role of microRNAs in the pathogenesis of autoimmune diseases.** *Autoimmun Rev*. 2016; 15(12): 1171–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. Link M, Salur L, Kisand K, *et al.*: **Higher FoxP3 mRNA expression in peripheral blood mononuclear cells of GAD65 or IA-2 autoantibody-positive compared with autoantibody-negative persons.** *APMIS*. 2008; 116(10): 896–902.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Ryder LR, Bartels EM, Woetmann A, *et al.*: **FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis.** *APMIS*. 2012; 120(5): 387–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. **F** Catrina AI, Svensson CI, Malmström V, *et al.*: **Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis.** *Nat Rev Rheumatol*. 2017; 13(2): 79–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
42. Lepez T, Vandewoestyne M, Deforce D: **Fetal microchimeric cells in autoimmune thyroid diseases: harmful, beneficial or innocent for the thyroid gland?** *Chimerism*. 2013; 4(4): 111–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. **F** Stevens AM: **Maternal microchimerism in health and disease.** *Best Pract Res Clin Obstet Gynaecol*. 2016; 31: 121–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
44. Mynster Kronborg T, Frohnert Hansen J, Nielsen CH, *et al.*: **Effects of the Commercial Flame Retardant Mixture DE-71 on Cytokine Production by Human Immune Cells.** *PLoS One*. 2016; 11(4): e0154621.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Gleicher N, Barad DH: **Gender as risk factor for autoimmune diseases.** *J Autoimmun*. 2007; 28(1): 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. **F** Brix TH, Hegedüs L: **Twin studies as a model for exploring the aetiology of autoimmune thyroid disease.** *Clin Endocrinol (Oxf)*. 2012; 76(4): 457–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
47. Bech K, Bliddal H, Feldt-Rasmussen U, *et al.*: **Heterogeneity of autoimmune thyroiditis.** *Allergy*. 1984; 39(4): 239–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. DeGroot LJ: **Diagnosis and Treatment of Graves' Disease.** In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, *et al.*, editors. *Endotext*. South Dartmouth (MA); 2000.
[PubMed Abstract](#)
49. Vanderpump MP: **The epidemiology of thyroid disease.** *Br Med Bull*. 2011; 99: 39–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. **F** Pedersen IB, Knudsen N, Carlé A, *et al.*: **A cautious iodization programme bringing iodine intake to a low recommended level is associated with an increase in the prevalence of thyroid autoantibodies in the population.** *Clin Endocrinol (Oxf)*. 2011; 75(1): 120–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
51. Jorgensen KT, Pedersen BV, Nielsen NM, *et al.*: **Childbirths and risk of female predominant and other autoimmune diseases in a population-based Danish cohort.** *J Autoimmun*. 2012; 38(2–3): J81–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Hansen PS, Brix TH, Iachine I, *et al.*: **The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins.** *Eur J Endocrinol*. 2006; 154(1): 29–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Pedersen IB, Knudsen N, Jørgensen T, *et al.*: **Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency.** *Clin Endocrinol (Oxf)*. 2003; 58(1): 36–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Rasmussen AK, Feldt-Rasmussen U, Brandt M, *et al.*: **Thyrotropin stimulates specifically the expression of the autoantibody binding domains of the thyroperoxidase molecule.** *Autoimmunity*. 1999; 29(4): 323–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. **F** Smith TJ, Hegedüs L: **Graves' Disease.** *N Engl J Med*. 2016; 375: 1552–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
56. WITEBSKY E, ROSE NR, TERPLAN K, *et al.*: **Chronic thyroiditis and autoimmunization.** *J Am Med Assoc*. 1957; 164(13): 1439–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Rose NR: **Autoimmune diseases: tracing the shared threads.** *Hosp Pract (1995)*. 1997; 32(4): 147–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Sheehan NJ, Stanton-King K: **Polyautoimmunity in a young woman.** *Br J Rheumatol*. 1993; 32(3): 254–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Anaya JM, Castiblanco J, Rojas-Villarraga A, *et al.*: **The multiple autoimmune syndromes. A clue for the autoimmune tautology.** *Clin Rev Allergy Immunol*. 2012; 43(3): 256–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Humbert P, Dupond JL: **[Multiple autoimmune syndromes].** *Ann Med Interne (Paris)*. 1988; 139(3): 159–68.
[PubMed Abstract](#)
61. Eisenbarth GS, Gottlieb PA: **Autoimmune polyendocrine syndromes.** *N Engl J Med*. 2004; 350(20): 2068–79.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Halonen M, Eskelin P, Myhre AG, *et al.*: **AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype.** *J Clin Endocrinol Metab*. 2002; 87(6): 2568–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Myhre AG, Undlien DE, Lovås K, *et al.*: **Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features.** *J Clin Endocrinol Metab*. 2002; 87(2): 618–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Mackay IR: **Clustering and commonalities among autoimmune diseases.** *J Autoimmun*. 2009; 33(3–4): 170–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Zeher M, Horvath IF, Szanto A, *et al.*: **Autoimmune thyroid diseases in a large group of Hungarian patients with primary Sjögren's syndrome.** *Thyroid*. 2009; 19(1): 39–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Biró E, Szekaneecz Z, Czirájk L, *et al.*: **Association of systemic and thyroid autoimmune diseases.** *Clin Rheumatol*. 2006; 25(2): 240–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. **F** Nakamura H, Usa T, Motomura M, *et al.*: **Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders.** *J Endocrinol Invest*. 2008; 31(10): 861–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
68. Liao KP, Kurreeman F, Li G, *et al.*: **Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non-rheumatoid arthritis controls.** *Arthritis Rheum*. 2013; 65(3): 571–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Feldt-Rasmussen U, Høier-Madsen M, Bech K, *et al.*: **Anti-thyroid peroxidase antibodies in thyroid disorders and non-thyroid autoimmune diseases.** *Autoimmunity*. 1991; 9(3): 245–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. **F** Fallahi P, Ferrari SM, Ruffilli I, *et al.*: **The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients.** *Autoimmun Rev*. 2016; 15(12): 1125–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
71. Di Mario U, Perfetti R, Anastasi E, *et al.*: **Autoantibodies to insulin do appear in non-diabetic patients with autoimmune disorders: comparison with anti-immunoglobulin antibodies and other autoimmune phenomena.** *Acta Endocrinol (Copenh)*. 1990; 122(3): 303–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. **F** Boelaert K, Newby PR, Simmonds MJ, *et al.*: **Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease.** *Am J Med*. 2010; 123(2): 183.e1–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
73. Wiebolt J, Achterbergh R, den Boer A, *et al.*: **Clustering of additional autoimmunity behaves differently in Hashimoto's patients compared with Graves' patients.** *Eur J Endocrinol*. 2011; 164(5): 789–94.
[PubMed Abstract](#) | [Publisher Full Text](#)

74. Eaton WW, Pedersen MG, Atladóttir HO, *et al.*: **The prevalence of 30 ICD-10 autoimmune diseases in Denmark.** *Immunol Res.* 2010; 47(1–3): 228–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Eaton WW, Rose NR, Kalaydjian A, *et al.*: **Epidemiology of autoimmune diseases in Denmark.** *J Autoimmun.* 2007; 29(1): 1–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Somers EC, Thomas SL, Smeeth L, *et al.*: **Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder?** *Am J Epidemiol.* 2009; 169(6): 749–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Ottesen M, Feldt-Rasmussen U, Andersen J, *et al.*: **Thyroid function and autoimmunity in pernicious anemia before and during cyanocobalamin treatment.** *J Endocrinol Invest.* 1995; 18(2): 91–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Anaya JM: **The diagnosis and clinical significance of polyautoimmunity.** *Autoimmun Rev.* 2014; 13(4–5): 423–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Raterman HG, Voskuyl AE, Simsek S, *et al.*: **Increased progression of carotid intima media thickness in thyroid peroxidase antibodies-positive rheumatoid arthritis patients.** *Eur J Endocrinol.* 2013; 169(6): 751–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Willeit P, Thompson SG, Agewall S, *et al.*: **Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration.** *Eur J Prev Cardiol.* 2016; 23(2): 194–205.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Caforio AL, Wagner R, Gill JS, *et al.*: **Organ-specific cardiac antibodies: serological markers for systemic hypertension in autoimmune polyendocrinopathy.** *Lancet.* 1991; 337(8750): 1111–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. de Jesus GR, Agmon-Levin N, Andrade CA, *et al.*: **14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome.** *Autoimmun Rev.* 2014; 13(8): 795–813.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Chen LM, Zhang Q, Si GX, *et al.*: **Associations between thyroid autoantibody status and abnormal pregnancy outcomes in euthyroid women.** *Endocrine.* 2015; 48(3): 924–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
84. Thangaratnam S, Tan A, Knox E, *et al.*: **Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence.** *BMJ.* 2011; 342: d2616.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
85. Iijima T, Tada H, Hidaka Y, *et al.*: **Effects of autoantibodies on the course of pregnancy and fetal growth.** *Obstet Gynecol.* 1997; 90(3): 364–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
86. Mekinian A, Cohen J, Alijotas-Reig J, *et al.*: **Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?** *Am J Reprod Immunol.* 2016; 76(1): 8–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
87. Piga M, Serra A, Deiana L, *et al.*: **Brain perfusion abnormalities in patients with euthyroid autoimmune thyroiditis.** *Eur J Nucl Med Mol Imaging.* 2004; 31(12): 1639–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Montagna G, Imperiali M, Agazzi P, *et al.*: **Hashimoto's encephalopathy: A rare proteiform disorder.** *Autoimmun Rev.* 2016; 15(5): 466–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
89. Watt T, Hegedü sL, Björner JB, *et al.*: **Is Thyroid Autoimmunity per se a Determinant of Quality of Life in Patients with Autoimmune Hypothyroidism?** *Eur Thyroid J.* 2012; 1(3): 186–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Bové KB, Watt T, Vogel A, *et al.*: **Anxiety and depression are more prevalent in patients with graves' disease than in patients with nodular goitre.** *Eur Thyroid J.* 2014; 3(3): 173–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Avouac J, Airò P, Dieude P, *et al.*: **Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients.** *J Rheumatol.* 2010; 37(3): 608–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
92. Marinó M, Ricciardi R, Pinchera A, *et al.*: **Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases.** *J Clin Endocrinol Metab.* 1997; 82(2): 438–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Wiersinga WM, Duntas L, Fadeyev V, *et al.*: **2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism.** *Eur Thyroid J.* 2012; 1(2): 55–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
94. Coles AJ, Wing M, Smith S, *et al.*: **Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.** *Lancet.* 1999; 354(9191): 1691–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Mandac JC, Chaudhry S, Sherman KE, *et al.*: **The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification.** *Hepatology.* 2006; 43(4): 661–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Antonelli A, Ferri C, Fallahi P: **Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy.** *Nat Rev Gastroenterol Hepatol.* 2009; 6(11): 633–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Stefan M, Jacobson EM, Huber AK, *et al.*: **Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism.** *J Biol Chem.* 2011; 286(36): 31168–79.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Spain L, Diem S, Larkin J: **Management of toxicities of immune checkpoint inhibitors.** *Cancer Treat Rev.* 2016; 44: 51–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
99. Corsello SM, Barnabei A, Marchetti P, *et al.*: **Endocrine side effects induced by immune checkpoint inhibitors.** *J Clin Endocrinol Metab.* 2013; 98(4): 1361–75.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Bliddal S, Borresen SW, Feldt-Rasmussen U: **Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis.** *Front Endocrinol (Lausanne).* 2017; 8: 179.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Raterman HG, Jamnitski A, Lems WF, *et al.*: **Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study.** *J Rheumatol.* 2011; 38(2): 247–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. El Fassi D, Nielsen CH, Hasselbalch HC, *et al.*: **Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion.** *Thyroid.* 2006; 16(7): 709–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
103. Nielsen CH, El Fassi D, Hasselbalch HC, *et al.*: **B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.** *Expert Opin Biol Ther.* 2007; 7(7): 1061–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
104. Salvi M, Vannucchi G, Currò N, *et al.*: **Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.** *J Clin Endocrinol Metab.* 2015; 100(2): 422–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
105. Buch MH, Smolen JS, Betteridge N, *et al.*: **Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.** *Ann Rheum Dis.* 2011; 70(6): 909–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
106. Hauser SL, Waubant E, Arnold DL, *et al.*: **B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.** *N Engl J Med.* 2008; 358(7): 676–88.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
107. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, *et al.*: **Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.** *N Engl J Med.* 2009; 361(22): 2143–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
108. Smith TJ, Kahaly GJ, Ezra DG, *et al.*: **Teprotumumab for Thyroid-Associated Ophthalmopathy.** *N Engl J Med.* 2017; 376(18): 1748–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
109. Baker KF, Isaacs JD: **Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?** *Ann Rheum Dis.* 2017; pii: annrheumdis-2017-211555.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Alessandro Antonelli**

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, Pisa, 56126, Italy

Competing Interests: No competing interests were disclosed.

2. **Maria Marazuela**

Service of Endocrinology, Hospital Universitario de la Princesa, Instituto de Investigacion Princesa, Universidad Autónoma de Madrid, Madrid, Spain

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research